Abstract
BackgroundAdalimumab (ADA) treatment in combination with methotrexate (MTX) is one of the established effective treatments for patients with rheumatoid arthritis (RA). However, the treatment with biologic disease-modifying anti-rheumatic drugs (bDMARDs)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
